The pCR rates were significantly higher in those with small tumor size, higher nuclear grade, estrogen receptor (ER)-negative/human epidermal growth factor receptor 2 (HER2)-negative (triple-negative [TN]) and HER2-positive subtypes, high levels of Ki67, and an anthracycline and taxane regimen (electronic supplementary Table 1 and data). The gene discussed is ERBB2; the disease is neoplasm.